A balance of interleukin-12 and -23 in cancer

Trends Immunol. 2013 Nov;34(11):548-55. doi: 10.1016/j.it.2013.07.004. Epub 2013 Aug 13.

Abstract

Interleukin (IL)-12 and IL-23 share the IL-12p40 molecule. IL-12 promotes T helper (Th)1 immunity and IL-23 promotes Th17 immunity, and it has recently become apparent that the balance between IL-12 and IL-23 is important in carcinogenesis. A series of studies demonstrated that, where tumor initiation, growth, and metastasis are concerned, IL-12 may act independently of interferon (IFN)-γ, and IL-23 independently of IL-17A. This review explores the activity of IL-23 in carcinogenesis. In the context of the tumor-inhibitory effects of IL-12, and tumor-promoting effects of IL-23, we discuss the use of anti-IL-12p/23 monoclonal antibodies (mAbs) in autoimmune inflammatory disorders and the alternative specific neutralization of IL-23.

Keywords: autoimmunity; cancer; cytokine; inflammation.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Antibodies, Monoclonal / immunology
  • Autoimmune Diseases / immunology
  • Carcinogenesis / immunology*
  • Humans
  • Interleukin-12 / immunology*
  • Interleukin-23 / immunology*
  • Neoplasms / immunology*
  • Neoplasms / pathology*

Substances

  • Antibodies, Monoclonal
  • Interleukin-23
  • Interleukin-12